2023-10-09 13:09:55.197  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : {"ips":{"resourceType":"Bundle","meta":{"lastUpdated":"2023-10-09T13:09:54.673+02:00"},"language":"da","identifier":{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:533295fc-5004-4407-8851-6bd5dc5e62bb"},"type":"document","timestamp":"2023-10-09T13:09:54.673+02:00","entry":[{"fullUrl":"urn:uuid:acbcba3a-0332-442f-9108-3e104ffeae09","resource":{"resourceType":"Composition","status":"final","type":{"coding":[{"system":"http://loinc.org","code":"60591-5","display":"Patient summary Document"}]},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"date":"2023-10-09T13:09:54+02:00","author":[{"display":"Lars Larsen"}],"title":"Patient Summary as of Mon Oct 09 13:09:54 CEST 2023","section":[{"title":"Medication","code":{"coding":[{"system":"http://loinc.org","code":"10160-0","display":"History of Medication use Narrative"}]},"entry":[{"reference":"urn:uuid:a8e69d5c-8eee-4328-8992-6901d7be7354"},{"reference":"urn:uuid:737bc2a6-7828-4a20-aa48-97c96fd8e11c"},{"reference":"urn:uuid:674068d9-d67e-47d6-88fc-eec79cea5153"},{"reference":"urn:uuid:afa8932b-cd4a-4346-80d6-b2f4931970eb"},{"reference":"urn:uuid:81f0d7f3-84a7-4e49-8649-a70cafd500ee"},{"reference":"urn:uuid:da1d9736-9f31-4a37-9f4a-acca7b66ae43"},{"reference":"urn:uuid:a7f30b4d-b324-4719-940a-a99bbc5cb89c"},{"reference":"urn:uuid:d4f6295d-9600-4a27-a31f-03a917ed4346"},{"reference":"urn:uuid:8c2f2ef9-d279-4c30-991f-23c91c2e73b9"},{"reference":"urn:uuid:8591797e-6b43-484f-bbec-02f23bc41fda"},{"reference":"urn:uuid:41e685d2-36d2-4a01-bd3b-b195b548f70d"},{"reference":"urn:uuid:5212f5b3-d0e9-4f6f-8618-e0670ad67d35"},{"reference":"urn:uuid:b47f0b5b-d03e-4bdc-8677-aa3f9b90ce67"},{"reference":"urn:uuid:4ff810d5-0f8d-4e03-ad01-a6ec84d3bc5a"},{"reference":"urn:uuid:42ec0dd4-50e6-4980-a668-72c7e3e93f18"},{"reference":"urn:uuid:f3d490ac-bc5c-4d60-a65b-a0b18e3af059"}]},{"title":"Pregnancy","entry":[{"reference":"Observation/4b3205f5-02a2-4b65-8ad3-2021ac90effb"}]}]}},{"fullUrl":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6","resource":{"resourceType":"Patient","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eCarla Gravitate \u003cb\u003eCARLSEN \u003c/b\u003e\u003c/div\u003e\u003ctable class\u003d\"hapiPropertyTable\"\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd\u003eIdentifier\u003c/td\u003e\u003ctd\u003e1509018436\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003eAddress\u003c/td\u003e\u003ctd\u003e\u003cspan\u003eMorbærvej 377 \u003c/span\u003e\u003cbr/\u003e\u003cspan\u003eKøbenhavn V \u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003eDate of birth\u003c/td\u003e\u003ctd\u003e\u003cspan\u003e15 September 2001\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/table\u003e\u003c/div\u003e"},"identifier":[{"system":"urn:oid:<IP_ADDRESS>.1.2","value":"1509018436"}],"name":[{"use":"official","family":"Carlsen","given":["Carla","Gravitate"]}],"gender":"female","birthDate":"2001-09-15","address":[{"use":"home","type":"postal","line":["Morbærvej 377"],"city":"København V","postalCode":"1701"}]}},{"fullUrl":"urn:uuid:7334c763-678d-4ef8-81d7-e0f3d7c72ffe","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eVitacare Modigen\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/922222"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"922222"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/922222"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:9f583a48-bf55-4254-bad4-050a79c8979b"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"N06AX25","display":"Perikon"},{"system":"http://medicinpriser.dk/drugid","code":"52610059497","display":"Vitacare Modigen"}],"text":"Vitacare Modigen"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"KAPH"}],"text":"kapsler, hårde"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"Perikontørekstrakt, kvantificeret (Prikbladet Perikon)"}]},"isActive":true}]}},{"fullUrl":"urn:uuid:a8e69d5c-8eee-4328-8992-6901d7be7354","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"display":"Tristhed"}}],"status":"active","medicationReference":{"reference":"urn:uuid:7334c763-678d-4ef8-81d7-e0f3d7c72ffe"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"1 kapsel morgen, middag og aften","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:7b50b705-e32d-46cf-aecf-c9f5d3e9e782","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eHumalog Mix25 KwikPen\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/156517"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"156517"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/156517"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:927e25bc-3643-4117-a935-a86e319b6d46"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"A10AD04","display":"Insulin lispro"},{"system":"http://medicinpriser.dk/drugid","code":"28104865811","display":"Humalog Mix25 KwikPen"}],"text":"Humalog Mix25 KwikPen"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"INJVSK"}],"text":"injektionsvæske"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"insulin lispro protamin"}]},"isActive":true,"strength":{"numerator":{"value":100.0,"unit":"enheder/ml","system":"http://medicinpriser.dk/styrkeenhed","code":"UML"},"denominator":{"value":1,"unit":"injektionsvæske","system":"http://medicinpriser.dk/formbetegnelse","code":"INJVSK"}}},{"itemCodeableConcept":{"coding":[{"display":"Insulin lispro"}]},"isActive":true,"strength":{"numerator":{"value":100.0,"unit":"enheder/ml","system":"http://medicinpriser.dk/styrkeenhed","code":"UML"},"denominator":{"value":1,"unit":"injektionsvæske","system":"http://medicinpriser.dk/formbetegnelse","code":"INJVSK"}}}]}},{"fullUrl":"urn:uuid:737bc2a6-7828-4a20-aa48-97c96fd8e11c","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"31","display":"mod diabetes"}}],"status":"active","medicationReference":{"reference":"urn:uuid:7b50b705-e32d-46cf-aecf-c9f5d3e9e782"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"According to schema in local system","asNeededBoolean":true,"route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"SC","display":"Subkutan anvendelse"}]}}]}},{"fullUrl":"urn:uuid:a0f501c5-4814-4829-867f-afed87f4e7e3","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eDomperidon \u0026quot;Alternova\u0026quot;\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/19971"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"19971"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/19971"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:09c91dfe-f872-4a2e-8474-56c7ad814e1a"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"A03FA03","display":"Domperidon"},{"system":"http://medicinpriser.dk/drugid","code":"28103635304","display":"Domperidon \"Alternova\""}],"text":"Domperidon \"Alternova\""},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"TAB"}],"text":"tabletter"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"DOMPERIDON"}]},"isActive":true,"strength":{"numerator":{"value":10.0,"unit":"mg","system":"http://medicinpriser.dk/styrkeenhed","code":"MG"},"denominator":{"value":1,"unit":"tabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TAB"}}}]}},{"fullUrl":"urn:uuid:674068d9-d67e-47d6-88fc-eec79cea5153","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"14","display":"mod kvalme"}}],"status":"active","medicationReference":{"reference":"urn:uuid:a0f501c5-4814-4829-867f-afed87f4e7e3"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"1 tablet daglig.\nBemærk: før et måltid","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:2d30e836-d92b-4245-9f30-567aba73b6b0","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eRemsima\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/69790"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"69790"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/69790"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:a6c29097-392b-48bc-bb62-a3ccc63854f4"},{"system":"https://www.gravitatehealth.eu/sid/doc","value":"EU/1/13/853/001"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"L04AB02","display":"Infliximab"},{"system":"http://medicinpriser.dk/drugid","code":"28105055512","display":"Remsima"}],"text":"Remsima"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"INFPUKO"}],"text":"pulver til koncentrat til infusionsvæske, opløsning"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"INFLIXIMAB"}]},"isActive":true,"strength":{"numerator":{"value":100.0,"unit":"mg","system":"http://medicinpriser.dk/styrkeenhed","code":"MG"},"denominator":{"value":1,"unit":"pulver til koncentrat til infusionsvæske, opløsning","system":"http://medicinpriser.dk/formbetegnelse","code":"INFPUKO"}}}]}},{"fullUrl":"urn:uuid:afa8932b-cd4a-4346-80d6-b2f4931970eb","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"221","display":"mod psoriasis"}}],"status":"active","medicationReference":{"reference":"urn:uuid:2d30e836-d92b-4245-9f30-567aba73b6b0"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"10 mg morgen og nat","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"IV","display":"Intravenøs anvendelse"}]}}]}},{"fullUrl":"urn:uuid:90bf022b-25ef-4f03-9de7-2af9f7f91cd7","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eCalcichew-D3 Forte\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/73764"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"73764"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/73764"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:83f0e5b0-cb4d-476e-9fff-aa88b5e499cc"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"A12AX","display":"Calcium, kombinationer med d-vitamin og/eller andre stoffer"},{"system":"http://medicinpriser.dk/drugid","code":"28105626815","display":"Calcichew-D3 Forte"}],"text":"Calcichew-D3 Forte"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"TYGTAB"}],"text":"tyggetabletter"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"Calciumcarbonat"}]},"isActive":true,"strength":{"numerator":{"system":"http://medicinpriser.dk/styrkeenhed"},"denominator":{"value":1,"unit":"tyggetabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TYGTAB"}}},{"itemCodeableConcept":{"coding":[{"display":"Cholecalciferol"}]},"isActive":true,"strength":{"numerator":{"system":"http://medicinpriser.dk/styrkeenhed"},"denominator":{"value":1,"unit":"tyggetabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TYGTAB"}}}]}},{"fullUrl":"urn:uuid:81f0d7f3-84a7-4e49-8649-a70cafd500ee","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"291","display":"tilskud af kalk og vitamin D"}}],"status":"active","medicationReference":{"reference":"urn:uuid:90bf022b-25ef-4f03-9de7-2af9f7f91cd7"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"1 tyggetablet morgen, middag, aften og nat","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:51f45a09-a062-4ac7-93ae-9ea79de36b00","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eOrlistat \u0026quot;Teva\u0026quot;\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/425073"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"425073"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/425073"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:9e897dcb-e7b9-490f-b2f7-144baab6af54"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"A08AB01","display":"Orlistat"},{"system":"http://medicinpriser.dk/drugid","code":"28104611209","display":"Orlistat \"Teva\""}],"text":"Orlistat \"Teva\""},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"KAPH"}],"text":"kapsler, hårde"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"ORLISTAT"}]},"isActive":true,"strength":{"numerator":{"value":120.0,"unit":"mg","system":"http://medicinpriser.dk/styrkeenhed","code":"MG"},"denominator":{"value":1,"unit":"kapsler, hårde","system":"http://medicinpriser.dk/formbetegnelse","code":"KAPH"}}}]}},{"fullUrl":"urn:uuid:da1d9736-9f31-4a37-9f4a-acca7b66ae43","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"341","display":"vægtreducerende"}}],"status":"active","medicationReference":{"reference":"urn:uuid:51f45a09-a062-4ac7-93ae-9ea79de36b00"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"1 kapsel 3 gange daglig.\nBemærk: ved et hovedmåltid","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:df0fb298-d9ee-4da6-a874-cd95bdc68fd5","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eTegretol\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/562527"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"562527"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/562527"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:af73f33f-ee2b-47ea-a550-5a3b1ce5a4f0"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"N03AF01","display":"Carbamazepin"},{"system":"http://medicinpriser.dk/drugid","code":"28105174612","display":"Tegretol"}],"text":"Tegretol"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"TAB"}],"text":"tabletter"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"CARBAMAZEPIN"}]},"isActive":true,"strength":{"numerator":{"value":200.0,"unit":"mg","system":"http://medicinpriser.dk/styrkeenhed","code":"MG"},"denominator":{"value":1,"unit":"tabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TAB"}}}]}},{"fullUrl":"urn:uuid:a7f30b4d-b324-4719-940a-a99bbc5cb89c","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"443","display":"ved trigeminusneuralgi"}}],"status":"active","medicationReference":{"reference":"urn:uuid:df0fb298-d9ee-4da6-a874-cd95bdc68fd5"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"1 tablet 3 gange daglig","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:d4ae9de9-dae9-4564-a1f1-b40707baa110","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eBiktarvy\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/436308"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"436308"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/436308"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:88760ba9-41a7-4e16-a803-d2c003cfa45a"},{"system":"https://www.gravitatehealth.eu/sid/doc","value":"EU/1/18/1289/001"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"J05AR20","display":"Emtricitabin, tenofovir alafenamid og bictegravir"},{"system":"http://medicinpriser.dk/drugid","code":"28105970117","display":"Biktarvy"}],"text":"Biktarvy"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}],"text":"filmovertrukne tabletter"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"tenofovir alafenamid"}]},"isActive":true,"strength":{"numerator":{"system":"http://medicinpriser.dk/styrkeenhed"},"denominator":{"value":1,"unit":"filmovertrukne tabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}}},{"itemCodeableConcept":{"coding":[{"display":"EMTRICITABIN"}]},"isActive":true,"strength":{"numerator":{"system":"http://medicinpriser.dk/styrkeenhed"},"denominator":{"value":1,"unit":"filmovertrukne tabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}}},{"itemCodeableConcept":{"coding":[{"display":"Bictegravirnatrium"}]},"isActive":true,"strength":{"numerator":{"system":"http://medicinpriser.dk/styrkeenhed"},"denominator":{"value":1,"unit":"filmovertrukne tabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}}}]}},{"fullUrl":"urn:uuid:d4f6295d-9600-4a27-a31f-03a917ed4346","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"883","display":"mod hiv-infektion"}}],"status":"active","medicationReference":{"reference":"urn:uuid:d4ae9de9-dae9-4564-a1f1-b40707baa110"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"1 tablet morgen, middag, aften og nat","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:6da7ac6c-9b57-406d-bec5-ffbfd6be5593","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eVaxigriptetra\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/30679"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"30679"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/30679"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:7aed46d9-73ac-4365-b023-85d891303024"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"J07BB02","display":"Influenza, renset antigen"},{"system":"http://medicinpriser.dk/drugid","code":"28105658315","display":"Vaxigriptetra"}],"text":"Vaxigriptetra"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"INJVSIS"}],"text":"injektionsvæske, suspension, fyldt injektionssprøjte"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"B/Phuket/3073/2013-lignende stamme (B/Phuket/3073/2013, vild type)"}]},"isActive":true},{"itemCodeableConcept":{"coding":[{"display":"A/Victoria/2570/2019 (H1N1)pdm09-lignende stamme (A/Victoria/2570/2019, IVR-215)"}]},"isActive":true},{"itemCodeableConcept":{"coding":[{"display":"B/Austria/1359417/2021 - lignende stamme (B/Michigan/01/2021, vildtype)"}]},"isActive":true},{"itemCodeableConcept":{"coding":[{"display":"A/Darwin/9/2021 (H3N2) - lignende stamme (A/Darwin/9/2021, IVR-228)"}]},"isActive":true}]}},{"fullUrl":"urn:uuid:8c2f2ef9-d279-4c30-991f-23c91c2e73b9","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"139","display":"influenzavaccine"}}],"status":"active","medicationReference":{"reference":"urn:uuid:6da7ac6c-9b57-406d-bec5-ffbfd6be5593"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00","end":"2023-06-21T00:00:00+02:00"}}],"text":"1 dosis","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"IM","display":"Intramuskulær anvendelse"}]}}]}},{"fullUrl":"urn:uuid:142e5e06-6d01-42f6-8bcf-2da375f132ea","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003ePentasa\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/528584"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"528584"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/528584"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:dc35d27e-cc82-477a-8ad8-0ba73fda6054"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"A07EC02","display":"Mesalazin"},{"system":"http://medicinpriser.dk/drugid","code":"28104562609","display":"Pentasa"}],"text":"Pentasa"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"DEPTAB"}],"text":"depottabletter"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"MESALAZIN"}]},"isActive":true,"strength":{"numerator":{"value":1.0,"unit":"g","system":"http://medicinpriser.dk/styrkeenhed","code":"G"},"denominator":{"value":1,"unit":"depottabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"DEPTAB"}}}]}},{"fullUrl":"urn:uuid:8591797e-6b43-484f-bbec-02f23bc41fda","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"22","display":"mod colitis ulcerosa"}}],"status":"active","medicationReference":{"reference":"urn:uuid:142e5e06-6d01-42f6-8bcf-2da375f132ea"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"2 tabletter 2 gange daglig","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:1b2123ea-1f52-408e-ae38-02da93f897e4","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003ePanodil\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/111955"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"111955"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/111955"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:6affb412-6407-48d0-8bf1-fe56083bd9d9"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"N02BE01","display":"Paracetamol"},{"system":"http://medicinpriser.dk/drugid","code":"28101674394","display":"Panodil"}],"text":"Panodil"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}],"text":"filmovertrukne tabletter"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"PARACETAMOL"}]},"isActive":true,"strength":{"numerator":{"value":1000.0,"unit":"mg","system":"http://medicinpriser.dk/styrkeenhed","code":"MG"},"denominator":{"value":1,"unit":"filmovertrukne tabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}}}]}},{"fullUrl":"urn:uuid:41e685d2-36d2-4a01-bd3b-b195b548f70d","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"145","display":"mod smerter"}}],"status":"active","medicationReference":{"reference":"urn:uuid:1b2123ea-1f52-408e-ae38-02da93f897e4"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"1 tablet 4 gange daglig","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:425a9d6c-e15c-477d-bbfb-937787096a3f","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eHumira\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/160037"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"160037"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/160037"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:36e076f8-1ed6-4bfd-891f-a5ed6828d583"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"L04AB04","display":"Adalimumab"},{"system":"http://medicinpriser.dk/drugid","code":"28105730115","display":"Humira"}],"text":"Humira"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"INJVOIS"}],"text":"injektionsvæske, opløsning i fyldt injektionssprøjte"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"ADALIMUMAB"}]},"isActive":true,"strength":{"numerator":{"value":100.0,"unit":"mg/ml","system":"http://medicinpriser.dk/styrkeenhed","code":"MGM"},"denominator":{"value":1,"unit":"injektionsvæske, opløsning i fyldt injektionssprøjte","system":"http://medicinpriser.dk/formbetegnelse","code":"INJVOIS"}}}]}},{"fullUrl":"urn:uuid:5212f5b3-d0e9-4f6f-8618-e0670ad67d35","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"display":"Gigt"}}],"status":"active","medicationReference":{"reference":"urn:uuid:425a9d6c-e15c-477d-bbfb-937787096a3f"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"According to schema in local system","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"SC","display":"Subkutan anvendelse"}]}}]}},{"fullUrl":"urn:uuid:4572b65a-4033-4dcf-aedc-35551a397cba","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eMirtazapin \u0026quot;Actavis\u0026quot;\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/21276"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"21276"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/21276"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:0d74aecb-d7d5-4a1c-a225-18382c0379aa"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"N06AX11","display":"Mirtazapin"},{"system":"http://medicinpriser.dk/drugid","code":"28104029506","display":"Mirtazapin \"Actavis\""}],"text":"Mirtazapin \"Actavis\""},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}],"text":"filmovertrukne tabletter"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"MIRTAZAPIN"}]},"isActive":true,"strength":{"numerator":{"value":30.0,"unit":"mg","system":"http://medicinpriser.dk/styrkeenhed","code":"MG"},"denominator":{"value":1,"unit":"filmovertrukne tabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}}}]}},{"fullUrl":"urn:uuid:b47f0b5b-d03e-4bdc-8677-aa3f9b90ce67","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"168","display":"mod depression"}}],"status":"active","medicationReference":{"reference":"urn:uuid:4572b65a-4033-4dcf-aedc-35551a397cba"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"1 tablet nat","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:325c12b0-59c9-4378-83d2-7bc2ed95fb68","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eDovato\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/423096"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"423096"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/423096"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:8e47337a-e681-4766-a09c-ee87e1e9fc5e"},{"system":"https://www.gravitatehealth.eu/sid/doc","value":"EU/1/19/1370"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"J05AR25","display":"Lamivudin og dolutegravir"},{"system":"http://medicinpriser.dk/drugid","code":"28106176218","display":"Dovato"}],"text":"Dovato"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}],"text":"filmovertrukne tabletter"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"Dolutegravir"}]},"isActive":true,"strength":{"numerator":{"system":"http://medicinpriser.dk/styrkeenhed"},"denominator":{"value":1,"unit":"filmovertrukne tabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}}},{"itemCodeableConcept":{"coding":[{"display":"LAMIVUDIN"}]},"isActive":true,"strength":{"numerator":{"system":"http://medicinpriser.dk/styrkeenhed"},"denominator":{"value":1,"unit":"filmovertrukne tabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TABFILM"}}}]}},{"fullUrl":"urn:uuid:4ff810d5-0f8d-4e03-ad01-a6ec84d3bc5a","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"883","display":"mod hiv-infektion"}}],"status":"active","medicationReference":{"reference":"urn:uuid:325c12b0-59c9-4378-83d2-7bc2ed95fb68"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"text":"Tages efter skriftlig anvisning fra afdeling","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:301672d0-6895-4267-8f81-97ca299297f6","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eIrbesartan \u0026quot;Medical Valley\u0026quot;\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/507874"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"507874"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/507874"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:23f11f8b-8820-4dcd-ada6-6b3c2f3d0178"},{"system":"https://www.gravitatehealth.eu/sid/doc","value":"EU/1/97/046/013"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"C09CA04","display":"Irbesartan"},{"system":"http://medicinpriser.dk/drugid","code":"28104452808","display":"Irbesartan \"Medical Valley\""}],"text":"Irbesartan \"Medical Valley\""},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"TAB"}],"text":"tabletter"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"IRBESARTAN"}]},"isActive":true,"strength":{"numerator":{"value":75.0,"unit":"mg","system":"http://medicinpriser.dk/styrkeenhed","code":"MG"},"denominator":{"value":1,"unit":"tabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"TAB"}}}]}},{"fullUrl":"urn:uuid:42ec0dd4-50e6-4980-a668-72c7e3e93f18","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"57","display":"mod forhøjet blodtryk"}}],"status":"active","medicationReference":{"reference":"urn:uuid:301672d0-6895-4267-8f81-97ca299297f6"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"1 tablet daglig","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"fullUrl":"urn:uuid:43c3e978-d37e-48b5-9138-ebd35e10321d","resource":{"resourceType":"Medication","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cdiv class\u003d\"hapiHeaderText\"\u003eSkilarence\u003c/div\u003e\u003c/div\u003e"},"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-leaflet-url","valueString":"https://www.indlaegssedler.dk/Search/Search/Search/112869"},{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dk-package-number","valueString":"112869"},{"url":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/","valueString":"https://www.indlaegssedler.dk/indlaegssedler/indlaegsseddel/112869"}],"identifier":[{"system":"urn:oid:2.16.7<IP_ADDRESS>.200.10","value":"urn:uuid:36dfd2bf-d177-43b0-b6ea-236d3e899b3a"},{"system":"https://www.gravitatehealth.eu/sid/doc","value":"EU/1/17/1201/002"}],"code":{"coding":[{"system":"http://www.whocc.no/atc","code":"L04AX07","display":"Dimethylfumarat"},{"system":"http://medicinpriser.dk/drugid","code":"28105709515","display":"Skilarence"}],"text":"Skilarence"},"form":{"coding":[{"system":"http://medicinpriser.dk/formbetegnelse","code":"ENTTAB"}],"text":"enterotabletter"},"ingredient":[{"itemCodeableConcept":{"coding":[{"display":"DIMETHYLFUMARAT"}]},"isActive":true,"strength":{"numerator":{"value":120.0,"unit":"mg","system":"http://medicinpriser.dk/styrkeenhed","code":"MG"},"denominator":{"value":1,"unit":"enterotabletter","system":"http://medicinpriser.dk/formbetegnelse","code":"ENTTAB"}}}]}},{"fullUrl":"urn:uuid:f3d490ac-bc5c-4d60-a65b-a0b18e3af059","resource":{"resourceType":"MedicationStatement","extension":[{"url":"http://medicinpriser.dk/indikation","valueCoding":{"system":"http://medicinpriser.dk/indikation","code":"875","display":"mod plaque-psoriasis"}}],"status":"active","medicationReference":{"reference":"urn:uuid:43c3e978-d37e-48b5-9138-ebd35e10321d"},"subject":{"reference":"urn:uuid:f6d3345e-402c-4420-947c-1f723b29fea6"},"effectivePeriod":{"start":"2023-06-21T00:00:00+02:00"},"dosage":[{"extension":[{"url":"http://gravitatehealth.eu/fhir/StructureDefinition/gravitate-dosageperiod","valuePeriod":{"start":"2023-06-21T00:00:00+02:00"}}],"text":"2 tabletter morgen og aften","route":{"coding":[{"system":"http://medicinpriser.dk/administrationsvej","code":"OR","display":"Oral anvendelse"}]}}]}},{"resource":{"resourceType":"Observation","id":"4b3205f5-02a2-4b65-8ad3-2021ac90effb","status":"final","valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"77386006"}]}}}]}}
2023-10-09 13:09:55.197  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : --> END POST (42538-byte body)
2023-10-09 13:09:55.647  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : <-- 200 https://fosps.gravitatehealth.eu/focusing/focus/processedbundledovato-en (449ms)
2023-10-09 13:09:55.647  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : x-powered-by: Express
2023-10-09 13:09:55.647  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : content-type: application/json; charset=utf-8
2023-10-09 13:09:55.647  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : content-length: 40923
2023-10-09 13:09:55.647  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : etag: W/"9fdb-Z8SKrYU36/a4TtJ0gEBTaoM52N4"
2023-10-09 13:09:55.647  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : date: Mon, 09 Oct 2023 11:09:55 GMT
2023-10-09 13:09:55.647  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : x-envoy-upstream-service-time: 327
2023-10-09 13:09:55.647  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : server: istio-envoy
2023-10-09 13:09:55.665  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     :
2023-10-09 13:09:55.666  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : {"resourceType":"Bundle","id":"processedbundledovato-en","meta":{"versionId":"13","lastUpdated":"2023-10-05T10:19:14.235+00:00","source":"#36c19c5d-9712-9e","profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"]},"language":"en","identifier":{"system":"https://www.gravitatehealth.eu/sid/doc","value":"EU/1/19/1370/001"},"type":"document","timestamp":"2023-04-25T11:55:27Z","entry":[{"fullUrl":"Composition/processed-composition16598f252d07b4784b82ba43cf9e847e","resource":{"resourceType":"Composition","id":"processed-composition16598f252d07b4784b82ba43cf9e847e","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"]},"language":"en","extension":[{"url":"http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/HtmlElementLink","extension":[{"url":"elementClass","valueString":"pregnancyCategory"},{"url":"concept","valueCodeableReference":{"concept":{"coding":[{"system":"http://snomed.info/sct","code":"77386006","display":"Pregnancy"}]}}}]},{"url":"http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/HtmlElementLink","extension":[{"url":"elementClass","valueString":"indication"},{"url":"concept","valueCodeableReference":{"concept":{"coding":[{"system":"https://icpc2.icd.com/","code":"B90","display":"HIV-infection/AIDS"}]}}}]},{"url":"http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/HtmlElementLink","extension":[{"url":"elementClass","valueString":"breastfeedingCategory"},{"url":"concept","valueCodeableReference":{"concept":{"coding":[{"system":"http://snomed.info/sct","code":"69840006","display":"Normal breast feeding (finding)"}]}}}]},{"url":"http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/HtmlElementLink","extension":[{"url":"elementClass","valueString":"liver"},{"url":"concept","valueCodeableReference":{"concept":{"coding":[{"system":"https://icpc2.icd.com/","code":"D97","display":"Liver disease, other"}]}}}]},{"url":"http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/HtmlElementLink","extension":[{"url":"elementClass","valueString":"contra-indication-hypericum"},{"url":"concept","valueCodeableReference":{"concept":{"coding":[{"system":"https://gsrs.ncats.nih.gov/ginas/app/beta","code":"XK4IUX8MNB","display":"Hypericum perforatum L."}]}}}]}],"identifier":[{"system":"https://spor.ema.europa.eu/rmswi/","value":"xx"}],"status":"final","type":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000155538"}],"text":"Package Leaflet"},"category":[{"coding":[{"system":"http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs","code":"P","display":"Processed"}]}],"subject":[{"reference":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e"}],"date":"2022-02-16T13:28:17Z","author":[{"reference":"Organization/mra-7c9b97127f73ff3605a10eb1c2cc24d1"}],"title":"TEST PURPOSES ONLY - Dovato 50 mg/300 mg film-coated tablets","attester":[{"mode":{"coding":[{"system":"http://hl7.org/fhir/composition-attestation-mode","code":"official"}]},"time":"2022-02-16T13:28:17Z"}],"section":[{"title":"B. Package Leaflet","code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000155538"}],"text":"B. PACKAGE LEAFLET"},"text":{"status":"additional","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">Package leaflet: Information for the patient Dovato 50 mg/300 mg film-coated tablets dolutegravir/lamivudine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.<ul><li>Keep this leaflet. You may need to read it again.</li><li>If you have any further questions, ask your doctor or pharmacist.</li><li>This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.</li><li>If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.</li></ul></div>"},"section":[{"title":"Package leaflet: Information for the user","code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000155538"}],"text":"Package leaflet: Information for the user"},"text":{"status":"additional","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><strong>Dovato 50 mg/300 mg film-coated tablets</strong></p><p><em>dolutegravir/lamivudine</em></p><p><strong>Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.</strong></p><ul><li>Keep this leaflet. You may need to read it again.</li><li>If you have any further questions, ask your doctor, or pharmacist.</li><li>This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.</li><li>If you get any side effects, talk to your doctor, or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.</li></ul></div>"}},{"title":"What is in this leaflet","code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000155538"}],"text":"What is in this leaflet"},"text":{"status":"additional","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">What in this leaflet<ol><li>What Dovato is and what it is used for</li><li>What you need to know before you take Dovato</li><li>How to take Dovato</li><li>Possible side effects</li><li>How to store Dovato</li><li>Contents of the pack and other information</li></ol></div>"}},{"title":"1. What Dovato 50 mg/300 mg film-coated tablets is and what it is used for","code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000155538"}],"text":"1. What Dovato 50 mg/300 mg film-coated tablets is and what it is used for"},"text":{"status":"additional","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Dovato is a medicine that contains two active ingredients used to treat human immunodeficiency virus (HIV) infection: dolutegravir and lamivudine. Dolutegravir belongs to a group of anti-retroviral medicines called integrase inhibitors (INIs), and lamivudine belongs to a group of anti-retroviral medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).</p><div class=\"indication\"><p>Dovato is used to treat HIV in adults and adolescents over 12 years old who weigh at least 40 kg.</p><p>Dovato does not cure HIV infection; it keeps the amount of virus in your body at a low level. This helps maintain the number of CD4 cells in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.</p></div><p>Not everyone responds to treatment with Dovato in the same way. Your doctor will monitor the effectiveness of your treatment.</p></div>"}},{"title":"2. What you need to know before you take Dovato 50 mg/300 mg film-coated tablets","code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000155538"}],"text":"2. What you need to know before you take Dovato 50 mg/300 mg film-coated tablets"},"text":{"status":"additional","div":"<p>Do not take Dovato</p><ul><li>if you are allergic (hypersensitive) to dolutegravir or lamivudine or any of the other ingredients of this medicine (listed in section 6).</li><li>If you are taking a medicine called fampridine (also known as dalfampridine; used in multiple sclerosis).</li><li>If you think any of these apply to you, tell your doctor. Warnings and precautions Some people taking Dovato or other combination treatments for HIV are more at risk of serious side effects than others. You need to be aware of the extra risks:</li><li><div class=\"liver\">if you have moderate or severe liver disease</div>if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection, don’t stop Dovato without your doctor’s advice, as your hepatitis may come back) • if you have a kidney problem. → Talk to your doctor before using Dovato if any of these apply to you. You may need extra checkups, including blood tests, while you’re taking your medicine. See section 4 for more information. Allergic reactions Dovato contains dolutegravir. Dolutegravir can cause a serious allergic reaction known as a hypersensitivity reaction. You need to know about important signs and symptoms to look out for while you’re taking Dovato. → Read the information ‘Allergic reactions’ in section 4 of this leaflet. Look out for important symptoms Some people taking medicines for HIV infection develop other conditions, which can be serious. These include: • symptoms of infections and inflammation • joint pain, stiffness and bone problems. You need to know about important signs and symptoms to look out for while you’re taking Dovato. → Read the information ‘Other possible side effects’ in section 4 of this leaflet.</li></ul><p><strong>Children</strong></p><p>This medicine is not for use in children under 12 years of age, because it has not been studied in these patients.</p><p><strong>Other medicines and Dovato</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>Don't take Dovato with the following medicine:</p><ul><li>fampridine (also known as dalfampridine), used in <strong>multiple sclerosis.</strong></li></ul><p>Some medicines can affect how Dovato works or make it more likely that you will have side effects. Dovato can also affect how some other medicines work.</p><p>Tell your doctor if you are taking any of the medicines in the following list:</p><ul><li>metformin, to treat diabetes</li><li>medicines called antacids, to treat indigestion and heartburn. Do not take an antacid during the 6 hours before you take Dovato, or for at least 2 hours after you take it (see also section 3, ‘How to take Dovato’)</li><li>supplements or multivitamins containing calcium, iron or magnesium. If you take Dovato with food, you can take supplements or multivitamins containing calcium, iron or magnesium at the same time as Dovato. If you do not take Dovato with food, do not take a supplement or multivitamin containing calcium, iron or magnesium during the 6 hours before you take Dovato, or for at least 2 hours after you take it (see also section 3, ‘How to take Dovato’)</li><li>emtricitabine, etravirine, efavirenz, nevirapine or tipranavir/ritonavir, to treat HIV infection</li><li>medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly</li><li>cladribine, to treat leukaemia or multiple sclerosis</li><li>rifampicin, to treat tuberculosis (TB) and other bacterial infections</li><li>phenytoin and phenobarbital, to treat epilepsy</li><li>oxcarbazepine and carbamazepine, to treat epilepsy or bipolar disorder</li><div class=\"contra-indication-hypericum\"><li><p>St. John’s wort (Hypericum perforatum), a herbal remedy to treat depression.</p></li></div><li><p>Tell your doctor or pharmacist if you are taking any of these. Your doctor may decide to adjust your dose or that you need extra check ups.</p></li></ul><div class=\"pregnancyCategory highlight\"><p><strong>Pregnancy</strong></p><p>If you are pregnant, think you may be pregnant, or if you are planning to have a baby:</p><ul><li>Talk to your doctor about the risks and benefits of taking Dovato.</li></ul><p>Taking Dovato at the time of becoming pregnant or during the first six weeks of pregnancy, may increase the risk of a birth defect, called neural tube defect, such as spina bifida (malformed spinal cord).</p><p>If you could get pregnant while taking Dovato:</p><ul><li>Talk to your doctor and discuss whether there is a need for contraception, such as condom or pills.</li></ul><p>Tell your doctor immediately if you become pregnant or are planning to become pregnant. Your doctor will review your treatment. Do not stop taking Dovato without consulting your doctor, as this may harm you and your unborn child.</p><p><strong>Breast-feeding</strong></p><p>Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk. A small amount of the ingredients in Dovato can also pass into your breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.</p></div><p><strong>Driving and using machines</strong></p><p>Dovato can make you dizzy, and have other side effects that make you less alert.</p><ul><li>Don’t drive or operate machinery unless you are sure you’re not affected.</li></ul>"}},{"title":"3. How to take Dovato 50 mg/300 mg film-coated tablets","code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000155538"}],"text":"3. How to take Dovato 50 mg/300 mg film-coated tablets"},"text":{"status":"additional","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><ul><li>The recommended dose of Dovato is one tablet once a day.</li></ul><p>Swallow the tablet with some liquid. Dovato can be taken with or without food.</p><p><strong>Use in adolescents</strong></p><p>Adolescents aged between 12 and 17 years and weighing at least 40 kg can take the adult dose of one tablet once a day.</p><p><strong>Antacid medicines</strong></p><p>Antacids, to treat indigestion and heartburn, can stop Dovato being absorbed into your body and make it less effective. Do not take an antacid during the 6 hours before you take Dovato, or for at least 2 hours after you take it. You can take other acid-lowering medicines like ranitidine and omeprazole at the same time as Dovato.</p><ul><li>Talk to your doctor for further advice on taking acid-lowering medicines with Dovato.</li></ul><p><strong>Supplements or multivitamins containing calcium, iron or magnesium</strong></p><p>Supplements or multivitamins containing calcium, iron or magnesium can stop Dovato being absorbed into your body and make it less effective. If you take Dovato with food, you can take supplements or multivitamins containing calcium, iron or magnesium at the same time as Dovato. If you do not take Dovato with food, do not take a supplement or multivitamin containing calcium, iron or magnesium during the 6 hours before you take Dovato, or for at least 2 hours after you take it.</p><ul><li>Talk to your doctor for further advice on taking supplements or multivitamins containing calcium, iron or magnesium with Dovato.</li></ul><p><strong>If you take more Dovato than you should</strong></p><p>If you take too many tablets of Dovato contact your doctor or pharmacist for advice. If possible, show them the Dovato pack.</p><p><strong>If you forget to take Dovato</strong></p><p>If you miss a dose, take it as soon as you remember. But if your next dose is due within 4 hours, skip the dose you missed and take the next one at the usual time. Then continue your treatment as before.</p><ul><li>Do not take a double dose to make up for a forgotten dose.</li></ul><p><strong>Don’t stop taking Dovato without advice from your doctor</strong></p><p>Take Dovato for as long as your doctor recommends. Don’t stop unless your doctor tells you to. Stopping Dovato can affect your health and how future treatment works.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"}},{"title":"4. Possible side effects","code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000155538"}],"text":"4. Possible side effects"},"text":{"status":"additional","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them, so it is very important to talk to your doctor about any changes in your health.</p><p><strong>Allergic reactions</strong></p><p>Dovato contains dolutegravir. Dolutegravir can cause a serious allergic reaction known as a hypersensitivity reaction. This is an uncommon reaction (may affect up to 1 in 100 people) in people taking dolutegravir. If you get any of the following symptoms:</p><ul><li>skin rash</li><li>a high temperature (fever)</li><li>lack of energy (fatigue)</li><li>swelling, sometimes of the face or mouth (angioedema), causing difficulty in breathing</li><li>muscle or joint aches.</li><li>See a doctor straight away. Your doctor may decide to carry out tests to check your liver, kidneys or blood, and may tell you to stop taking Dovato.</li></ul><p><strong>Very common side effects</strong></p><p>These may affect more than 1 in 10 people:</p><ul><li>headache</li><li>diarrhoea</li><li>feeling sick (nausea).</li></ul><p><strong>Common side effects</strong></p><p>These may affect up to 1 in 10 people:</p><ul><li>depression (feelings of deep sadness and unworthiness)</li><li>rash</li><li>itching (pruritus)</li><li>being sick (vomiting)</li><li>stomach (abdominal) pain or discomfort</li><li>weight gain</li><li>wind (flatulence)</li><li>dizziness</li><li>feeling drowsy</li><li>difficulty sleeping (insomnia)</li><li>abnormal dreams</li><li>lack of energy (fatigue)</li><li>hair loss</li><li>anxiety</li><li>joint pain</li><li>muscle pain.</li></ul><p>Common side effects that may show up in blood tests are:</p><ul><li>increase in the level of liver enzymes (aminotransferases)</li><li>increase in the level of enzymes produced in the muscles (creatine phosphokinase).</li></ul><p><strong>Uncommon side effects</strong></p><p>These may affect up to 1 in 100 people:</p><ul><li>inflammation of the liver (hepatitis)</li><li>suicidal attempt (particularly in patients who have had depression or mental health problems before)</li><li>suicidal thoughts (particularly in patients who have had depression or mental health problems before).</li><li>panic attack</li></ul><p>Uncommon side effects that may show up in blood tests are:</p><ul><li>a decreased number of cells involved in blood clotting (thrombocytopenia)</li><li>a low red blood cell count (anaemia) or low white blood cell count (neutropenia).</li></ul><p><strong>Rare side effects</strong></p><p>These may affect up to 1 in 1000 people:</p><ul><li>liver failure (signs may include yellowing of the skin and the whites of the eyes or unusually dark urine)</li><li>swelling, sometimes of the face or mouth (angioedema), causing difficulty in breathing</li><li>inflammation of the pancreas (pancreatitis)</li><li>breakdown of muscle tissue.</li><li>suicide (particularly in patients who have had depression or mental health problems before)</li><li>Tell your doctor immediately if you experience any mental health problems (see also other mental health problems above).</li></ul><p>Rare side effects that may show up in blood tests are:</p><ul><li>increase in bilirubin (a test of liver function)</li><li>increase in an enzyme called amylase.</li></ul><p>Very rare side effects These may affect up to 1 in 10,000 people:</p><ul><li>lactic acidosis (excess lactic acid in the blood)</li><li>numbness, tingly feelings in the skin (pins and needles)</li><li>sensation of weakness in the limbs.</li></ul><p>Very rare side effects that may show up in blood tests are:</p><ul><li>a failure of the bone marrow to produce new red blood cells (pure red cell aplasia).</li></ul><p><strong>Other possible side effects</strong></p><p>People taking combination therapy for HIV may get other side effects.</p><p><strong>Symptoms of infection and inflammation</strong></p><p>People with advanced HIV infection or AIDS have weak immune systems, and are more likely to develop serious infections (opportunistic infections). Such infections may have been “silent” and not detected by the weak immune system before treatment was started. After starting treatment, the immune system becomes stronger, and may attack the infections, which can cause symptoms of infection or inflammation. Symptoms usually include fever, plus some of the following:</p><ul><li>headache</li><li>stomach ache</li><li>difficulty breathing. In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (autoimmune disorders). The symptoms of autoimmune disorders may develop many months after you start taking medicine to treat your HIV infection. Symptoms may include:</li><li>palpitations (rapid or irregular heartbeat) or tremor</li><li>hyperactivity (excessive restlessness and movement)</li><li>weakness beginning in the hands and feet and moving up towards the trunk of the body. If you get any symptoms of infection or if you notice any of the symptoms above:</li><li>Tell your doctor immediately. Don’t take other medicines for the infection without your doctor’s advice.</li></ul><p><strong>Joint pain, stiffness and bone problems</strong></p><p>Some people taking combination therapy for HIV develop a condition called osteonecrosis. With this condition, parts of the bone tissue are permanently damaged because of reduced blood supply to the bone. People may be more likely to get this condition:</p><ul><li>if they have been taking combination therapy for a long time</li><li>if they are also taking anti-inflammatory medicines called corticosteroids</li><li>if they drink alcohol</li><li>if their immune systems are very weak</li><li>if they are overweight.</li></ul><p><strong>Signs of osteonecrosis include:</strong></p><ul><li>stiffness in the joints</li><li>aches and pains in the joints (especially in the hip, knee or shoulder)</li><li>difficulty moving. If you notice any of these symptoms:</li><li><strong>Tell your doctor.</strong></li></ul><p><strong>Weight, blood lipid and blood glucose effects:</strong></p><p>During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and lifestyle, and sometimes to the HIV medicines themselves. Your doctor will test for these changes.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"}},{"title":"5. How to store Dovato 50 mg/300 mg film-coated tablets","code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000155538"}],"text":"5. How to store Dovato 50 mg/300 mg film-coated tablets"},"text":{"status":"additional","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"}},{"title":"6. Contents of the pack and other information","code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000155538"}],"text":"6. Contents of the pack and other information"},"text":{"status":"additional","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Contents of the pack and other information What Dovato contains</p><ul><li>The active substances are dolutegravir and lamivudine. Each tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir and 300 mg lamivudine.</li><li>The other ingredients are microcrystalline cellulose, sodium starch glycolate, magnesium stearate, mannitol (E421), povidone (K29/32), sodium stearyl fumarate, hypromellose (E464), macrogol, titanium dioxide (E171).</li><li>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodiumfree’.</li></ul><p><strong>What Dovato looks like and contents of the pack</strong></p><p>Dovato film-coated tablets are oval, biconvex, white tablets debossed with 'SV 137' on one face.</p><p>The film-coated tablets are provided in bottles closed with child-resistant closures.</p><p>Each bottle contains 30 film-coated tablets.</p><p>Multipacks containing 90 film-coated tablets (3 packs of 30 film-coated tablets) are also available. Not all pack sizes may be available in your c ountry</p></div>"}}]}]}},{"fullUrl":"Ingredient/ingredient-for-dovato-dolutegravirsodium","resource":{"resourceType":"Ingredient","id":"ingredient-for-dovato-dolutegravirsodium","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]},"identifier":{"use":"official","system":"https://gsrs.ncats.nih.gov/ginas/app/beta","value":"1Q1V9V5WYQ"},"status":"active","for":[{"reference":"ManufacturedItemDefinition/mid-49178f16170ee8a6bc2a4361c1748d5f"},{"reference":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e"},{"reference":"AdministrableProductDefinition/ap-49178f16170ee8a6bc2a4361c1748d5f"}],"role":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"72072","display":"active"}]},"substance":{"code":{"concept":{"coding":[{"system":"https://gsrs.ncats.nih.gov/ginas/app/beta","code":"1Q1V9V5WYQ","display":"DOLUTEGRAVIR SODIUM"}]}},"strength":[{"presentationQuantity":{"value":50,"system":"http://unitsofmeasure.org","code":"mg"},"basis":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v3-RoleClass","code":"ACTIB","display":"active ingredient - basis of strength"}]}}]}}},{"fullUrl":"Ingredient/ingredient-for-dovato-lamivudine","resource":{"resourceType":"Ingredient","id":"ingredient-for-dovato-lamivudine","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]},"identifier":{"use":"official","system":"https://gsrs.ncats.nih.gov/ginas/app/beta","value":"2T8Q726O95"},"status":"active","for":[{"reference":"ManufacturedItemDefinition/mid-49178f16170ee8a6bc2a4361c1748d5f"},{"reference":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e"},{"reference":"AdministrableProductDefinition/ap-49178f16170ee8a6bc2a4361c1748d5f"}],"role":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"72072","display":"active"}]},"substance":{"code":{"concept":{"coding":[{"system":"https://gsrs.ncats.nih.gov/ginas/app/beta","code":"2T8Q726O95","display":"lamivudine"}]}},"strength":[{"presentationQuantity":{"value":300,"system":"http://unitsofmeasure.org","code":"mg"},"basis":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v3-RoleClass","code":"ACTIB","display":"active ingredient - basis of strength"}]}}]}}},{"fullUrl":"Ingredient/ingredient-for-dovato-microcrystallinecellulose","resource":{"resourceType":"Ingredient","id":"ingredient-for-dovato-microcrystallinecellulose","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]},"identifier":{"use":"official","system":"https://gsrs.ncats.nih.gov/ginas/app/beta","value":"OP1R32D61U"},"status":"active","for":[{"reference":"ManufacturedItemDefinition/mid-49178f16170ee8a6bc2a4361c1748d5f"},{"reference":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e"},{"reference":"AdministrableProductDefinition/ap-49178f16170ee8a6bc2a4361c1748d5f"}],"role":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000072082","display":"Excipient"}]},"substance":{"code":{"concept":{"coding":[{"system":"https://gsrs.ncats.nih.gov/ginas/app/beta","code":"OP1R32D61U","display":"microcrystalline cellulose"}]}}}}},{"fullUrl":"Ingredient/ingredient-for-dovato-sodiumstarchglycolate","resource":{"resourceType":"Ingredient","id":"ingredient-for-dovato-sodiumstarchglycolate","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]},"identifier":{"use":"official","system":"https://gsrs.ncats.nih.gov/ginas/app/beta","value":"H8AV0SQX4D"},"status":"active","for":[{"reference":"ManufacturedItemDefinition/mid-49178f16170ee8a6bc2a4361c1748d5f"},{"reference":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e"},{"reference":"AdministrableProductDefinition/ap-49178f16170ee8a6bc2a4361c1748d5f"}],"role":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000072082","display":"Excipient"}]},"substance":{"code":{"concept":{"coding":[{"system":"https://gsrs.ncats.nih.gov/ginas/app/beta","code":"H8AV0SQX4D","display":"sodium starch glycolate"}]}}}}},{"fullUrl":"Ingredient/ingredient-for-dovato-magnesiumstearate","resource":{"resourceType":"Ingredient","id":"ingredient-for-dovato-magnesiumstearate","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]},"identifier":{"use":"official","system":"https://gsrs.ncats.nih.gov/ginas/app/beta","value":"70097M6I30"},"status":"active","for":[{"reference":"ManufacturedItemDefinition/mid-49178f16170ee8a6bc2a4361c1748d5f"},{"reference":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e"},{"reference":"AdministrableProductDefinition/ap-49178f16170ee8a6bc2a4361c1748d5f"}],"role":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000072082","display":"Excipient"}]},"substance":{"code":{"concept":{"coding":[{"system":"https://gsrs.ncats.nih.gov/ginas/app/beta","code":"70097M6I30","display":"magnesium stearate"}]}}}}},{"fullUrl":"Ingredient/ingredient-for-dovato-mannitol","resource":{"resourceType":"Ingredient","id":"ingredient-for-dovato-mannitol","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]},"identifier":{"use":"official","system":"https://gsrs.ncats.nih.gov/ginas/app/beta","value":"3OWL53L36A"},"status":"active","for":[{"reference":"ManufacturedItemDefinition/mid-49178f16170ee8a6bc2a4361c1748d5f"},{"reference":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e"},{"reference":"AdministrableProductDefinition/ap-49178f16170ee8a6bc2a4361c1748d5f"}],"role":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000072082","display":"Excipient"}]},"substance":{"code":{"concept":{"coding":[{"system":"https://gsrs.ncats.nih.gov/ginas/app/beta","code":"3OWL53L36A","display":"mannitol"}]}}}}},{"fullUrl":"SubstanceDefinition/substance-dolutegravirsodium","resource":{"resourceType":"SubstanceDefinition","id":"substance-dolutegravirsodium","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi"]},"identifier":[{"use":"official","system":"https://gsrs.ncats.nih.gov/ginas/app/beta/","value":"1Q1V9V5WYQ"}],"version":"1","status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active"}]},"manufacturer":[{"reference":"Organization/man-173fde4cb6b1018cb7ec8ab708d3961c"}],"molecularWeight":[{"type":{"text":"exact"},"amount":{"value":441.36}}],"structure":{"molecularFormula":"C20H18F2N305.Na"},"name":[{"name":"(4R,12.ALPHA.S)-N-((2,4-DIFLUOROPHENYL)METHYL)-7-HYDROXY-4-METHYL-6,8-DIOXO-3,4,6,8,12,12.ALPHA.-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-.BETA.)(1,3)OXAZINE-9-CARBOXAMIDE","type":{"coding":[{"system":"https://gsrs.ncats.nih.gov/ginas/app/beta/","code":"x","display":"Chemical Name"}]}}]}},{"fullUrl":"SubstanceDefinition/substance-lamivudine","resource":{"resourceType":"SubstanceDefinition","id":"substance-lamivudine","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi"]},"identifier":[{"use":"official","system":"https://gsrs.ncats.nih.gov/ginas/app/beta/","value":"2T8Q726O95"}],"version":"1","status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active"}]},"manufacturer":[{"reference":"Organization/man-173fde4cb6b1018cb7ec8ab708d3961c"}],"molecularWeight":[{"type":{"text":"exact"},"amount":{"value":229.26}}],"structure":{"molecularFormula":"C8H11N303S"},"name":[{"name":"(-)-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE","type":{"coding":[{"system":"https://gsrs.ncats.nih.gov/ginas/app/beta/","code":"x","display":"Chemical Name"}]}}]}},{"fullUrl":"AdministrableProductDefinition/ap-49178f16170ee8a6bc2a4361c1748d5f","resource":{"resourceType":"AdministrableProductDefinition","id":"ap-49178f16170ee8a6bc2a4361c1748d5f","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi"]},"identifier":[{"system":"https://www.who-umc.org/phpid","value":"123456"}],"status":"active","formOf":[{"reference":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e"}],"administrableDoseForm":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"200000002152","display":"tablet"}]},"unitOfPresentation":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"200000002152","display":"tablet"}]},"producedFrom":[{"reference":"ManufacturedItemDefinition/mid-49178f16170ee8a6bc2a4361c1748d5f"}],"routeOfAdministration":[{"code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000073619","display":"Oral use"}]},"targetSpecies":[{"code":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000109093","display":"Human"}]}}]}]}},{"fullUrl":"RegulatedAuthorization/authorization49178f16170ee8a6bc2a4361c1748d5f","resource":{"resourceType":"RegulatedAuthorization","id":"authorization49178f16170ee8a6bc2a4361c1748d5f","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi"]},"identifier":[{"use":"official","system":"https://spor.ema.europa.eu/pmswi","value":"EU/1/19/1370/001"}],"subject":[{"reference":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e"}],"type":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000072062","display":"Marketing Authorisation"}]},"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]},"statusDate":"2019-07-01T13:28:17Z","holder":{"reference":"Organization/mah-31ff1af739c7dcf77386a86f8dd83d29"},"regulator":{"reference":"Organization/mra-7c9b97127f73ff3605a10eb1c2cc24d1"}}},{"fullUrl":"Organization/man-173fde4cb6b1018cb7ec8ab708d3961c","resource":{"resourceType":"Organization","id":"man-173fde4cb6b1018cb7ec8ab708d3961c","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"]},"identifier":[{"use":"official","system":"https://spor.ema.europa.eu/omswi","value":"ORG-100004538"}],"active":true,"type":[{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"220000000033","display":"Manufacturer"}]}],"name":"GLAXO WELLCOME, S.A.","contact":[{"address":{"use":"work","type":"physical","text":"Avda. Extremadura 3, 09400 Aranda De Duero Aranda De Duero ES","line":["Avda. Extremadura 3, 09400 Aranda De Duero"],"city":"Aranda De Duero","country":"ES"}}]}},{"fullUrl":"Organization/mah-31ff1af739c7dcf77386a86f8dd83d29","resource":{"resourceType":"Organization","id":"mah-31ff1af739c7dcf77386a86f8dd83d29","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"]},"identifier":[{"use":"official","system":"https://spor.ema.europa.eu/omswi","value":"ORG-100012958"}],"active":true,"type":[{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"220000000034","display":"Marketing authorisation holder"}]}],"name":"ViiV Healthcare BV","contact":[{"address":{"use":"work","type":"physical","text":"Van Asch van Wijckstraat 55H Amersfoort NL","line":["Van Asch van Wijckstraat 55H"],"city":"Amersfoort","country":"NL"}}]}},{"fullUrl":"Organization/mra-7c9b97127f73ff3605a10eb1c2cc24d1","resource":{"resourceType":"Organization","id":"mra-7c9b97127f73ff3605a10eb1c2cc24d1","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"]},"identifier":[{"use":"official","system":"https://spor.ema.europa.eu/omswi","value":"ORG-100013412"}],"active":true,"type":[{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"220000000032","display":"Medicines Regulatory Authority"}]}],"name":"European Medicines Agency","contact":[{"address":{"use":"work","type":"physical","text":"Carretera De Martorell 41 61, Poligono Industrial Nord-Est Amsterdam NL","line":["Carretera De Martorell 41 61, Poligono Industrial Nord-Est"],"city":"Amsterdam","postalCode":"1083 HS","country":"NL"}}]}},{"fullUrl":"PackagedProductDefinition/ppd-23f4e5c6d9ca952c3ffb3940859a26f8","resource":{"resourceType":"PackagedProductDefinition","id":"ppd-23f4e5c6d9ca952c3ffb3940859a26f8","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi"]},"identifier":[{"use":"official","system":"https://spor.ema.europa.eu/pmswi","value":"EU/1/19/1370/001"}],"name":"50 mg/300 mg film-coated tablets","type":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000155527","display":"Chemical Medicinal Prodcut"}]},"packageFor":[{"reference":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e"}],"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]},"statusDate":"2012-02-07T13:28:17Z","containedItemQuantity":[{"value":30,"system":"http://unitsofmeasure.org","code":"{tablets}"}],"manufacturer":[{"reference":"Organization/man-173fde4cb6b1018cb7ec8ab708d3961c"}],"packaging":{"identifier":[{"system":"https://spor.ema.europa.eu/pmswi","value":"mock-id"}],"type":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000073498","display":"Box"}]},"quantity":1,"packaging":[{"identifier":[{"system":"https://spor.ema.europa.eu/pmswi","value":"654321"}],"type":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000073504","display":"Child-resistant closure"}]},"quantity":1,"material":[{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"200000003529","display":"Cardboard"}]}]}]}}},{"fullUrl":"MedicinalProductDefinition/mp16598f252d07b4784b82ba43cf9e847e","resource":{"resourceType":"MedicinalProductDefinition","id":"mp16598f252d07b4784b82ba43cf9e847e","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"]},"identifier":[{"system":"https://spor.ema.europa.eu/pmswi","value":"EU/1/19/1370/001"},{"system":"https://www.who-umc.org/phpid","value":"0x073AF2E5B92AE19E8B67635AFFB3D6CA"}],"type":{"coding":[{"system":"http://hl7.org/fhir/medicinal-product-type","code":"MedicinalProduct","display":"Medicinal Product"}]},"domain":{"coding":[{"system":"http://hl7.org/fhir/medicinal-product-domain","code":"Human","display":"Human use"}]},"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"active"}]},"legalStatusOfSupply":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"100000072084","display":"Medicinal product subject to medical prescription"}]},"name":[{"productName":"Dovato 50 mg/300 mg film-coated tablets","type":{"coding":[{"system":"https://spor.ema.europa.eu/lists/220000000000","code":"220000000001"}],"text":"Full name"},"part":[{"part":"Dovato","type":{"coding":[{"system":"https://spor.ema.europa.eu/lists/220000000000","code":"220000000002"}],"text":"Invented name part"}},{"part":"dolutegravir/lamivudine","type":{"coding":[{"system":"https://spor.ema.europa.eu/lists/220000000000","code":"220000000003"}],"text":"Scientific name part"}},{"part":"50 mg/300 mg","type":{"coding":[{"system":"https://spor.ema.europa.eu/lists/220000000000","code":"220000000004"}],"text":"Strength part"}},{"part":"film-coated tablets","type":{"coding":[{"system":"https://spor.ema.europa.eu/lists/220000000000","code":"220000000005"}],"text":"Pharmaceutical dose form part"}}],"usage":[{"country":{"coding":[{"system":"urn:iso:std:iso:3166","code":"GBR","display":"United Kingdom"}]},"jurisdiction":{"coding":[{"system":"urn:iso:std:iso:3166","code":"GBR","display":"United Kingdom"}]},"language":{"coding":[{"system":"urn:ietf:bcp:47","code":"en","display":"English"}]}}]}]}},{"fullUrl":"ManufacturedItemDefinition/mid-49178f16170ee8a6bc2a4361c1748d5f","resource":{"resourceType":"ManufacturedItemDefinition","id":"mid-49178f16170ee8a6bc2a4361c1748d5f","meta":{"profile":["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi"]},"identifier":[{"use":"official","system":"https://spor.ema.europa.eu/pmswi","value":"EU/1/19/1370/001"}],"status":"active","manufacturedDoseForm":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi/","code":"100000073665","display":"Film-coated tablet"}]},"unitOfPresentation":{"coding":[{"system":"https://spor.ema.europa.eu/rmswi","code":"200000002152","display":"Tablet"}]},"manufacturer":[{"reference":"Organization/man-173fde4cb6b1018cb7ec8ab708d3961c"}]}}]}
2023-10-09 13:09:55.670  INFO 71912 --- [nio-8080-exec-3] okhttp3.OkHttpClient                     : <-- END HTTP (40923-byte body)

More specifically this section:
The markup in the document following the root element must be well-formed."): <p xmlns="http://www.w3.org/1999/xhtml">Do not take Dovato</p><ul><li>if you are allergic (hypersensitive) to dolutegravir or lamivudine or any of the other ingredients of this medicine (listed in section 6).</li><li>If you are taking a medicine called fampridine (also known as dalfampridine; used in multiple sclerosis).</li><li>If you think any of these apply to you, tell your doctor. Warnings and precautions Some people taking Dovato or other combination treatments for HIV are more at risk of serious side effects than others. You need to be aware of the extra risks:</li><li><div class="liver">if you have moderate or severe liver disease</div>if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection, don’t stop Dovato without your doctor’s advice, as your hepatitis may come back) • if you have a kidney problem. → Talk to your doctor before using Dovato if any of these apply to you. You may need extra checkups, including blood tests, while you’re taking your medicine. See section 4 for more information. Allergic reactions Dovato contains dolutegravir. Dolutegravir can cause a serious allergic reaction known as a hypersensitivity reaction. You need to know about important signs and symptoms to look out for while you’re taking Dovato. → Read the information ‘Allergic reactions’ in section 4 of this leaflet. Look out for important symptoms Some people taking medicines for HIV infection develop other conditions, which can be serious. These include: • symptoms of infections and inflammation • joint pain, stiffness and bone problems. You need to know about important signs and symptoms to look out for while you’re taking Dovato. → Read the information ‘Other possible side effects’ in section 4 of this leaflet.</li></ul><p><strong>Children</strong></p><p>This medicine is not for use in children under 12 years of age, because it has not been studied in these patients.</p><p><strong>Other medicines and Dovato</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>Don't take Dovato with the following medicine:</p><ul><li>fampridine (also known as dalfampridine), used in <strong>multiple sclerosis.</strong></li></ul><p>Some medicines can affect how Dovato works or make it more likely that you will have side effects. Dovato can also affect how some other medicines work.</p><p>Tell your doctor if you are taking any of the medicines in the following list:</p><ul><li>metformin, to treat diabetes</li><li>medicines called antacids, to treat indigestion and heartburn. Do not take an antacid during the 6 hours before you take Dovato, or for at least 2 hours after you take it (see also section 3, ‘How to take Dovato’)</li><li>supplements or multivitamins containing calcium, iron or magnesium. If you take Dovato with food, you can take supplements or multivitamins containing calcium, iron or magnesium at the same time as Dovato. If you do not take Dovato with food, do not take a supplement or multivitamin containing calcium, iron or magnesium during the 6 hours before you take Dovato, or for at least 2 hours after you take it (see also section 3, ‘How to take Dovato’)</li><li>emtricitabine, etravirine, efavirenz, nevirapine or tipranavir/ritonavir, to treat HIV infection</li><li>medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly</li><li>cladribine, to treat leukaemia or multiple sclerosis</li><li>rifampicin, to treat tuberculosis (TB) and other bacterial infections</li><li>phenytoin and phenobarbital, to treat epilepsy</li><li>oxcarbazepine and carbamazepine, to treat epilepsy or bipolar disorder</li><div class="contra-indication-hypericum"><li><p>St. John’s wort (Hypericum perforatum), a herbal remedy to treat depression.</p></li></div><li><p>Tell your doctor or pharmacist if you are taking any of these. Your doctor may decide to adjust your dose or that you need extra check ups.</p></li></ul><div class="pregnancyCategory highlight"><p><strong>Pregnancy</strong></p><p>If you are pregnant, think you may be pregnant, or if you are planning to have a baby:</p><ul><li>Talk to your doctor about the risks and benefits of taking Dovato.</li></ul><p>Taking Dovato at the time of becoming pregnant or during the first six weeks of pregnancy, may increase the risk of a birth defect, called neural tube defect, such as spina bifida (malformed spinal cord).</p><p>If you could get pregnant while taking Dovato:</p><ul><li>Talk to your doctor and discuss whether there is a need for contraception, such as condom or pills.</li></ul><p>Tell your doctor immediately if you become pregnant or are planning to become pregnant. Your doctor will review your treatment. Do not stop taking Dovato without consulting your doctor, as this may harm you and your unborn child.</p><p><strong>Breast-feeding</strong></p><p>Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk. A small amount of the ingredients in Dovato can also pass into your breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.</p></div><p><strong>Driving and using machines</strong></p><p>Dovato can make you dizzy, and have other side effects that make you less alert.</p><ul><li>Don’t drive or operate machinery unless you are sure you’re not affected.</li></ul>

Found this:

List items are like spans, only accepts text only nodes. Maybe a solution could be writing the class on the whole list item instead of adding a div as a childnode.

its the generic class detector available?
Alejandro Alonso @.***> escreveu no dia segunda,
9/10/2023 à(s) 13:09:

Found this:
[image: imagen]
https://user-images.githubusercontent.com/49404378/273579497-d89cbc93-20d5-4746-9395-030f854e5739.png
List items are like spans, only accepts text only nodes. Maybe a solution
could be writing the class on the whole list item instead of adding a div
as a childnode.
—
Reply to this email directly, view it on GitHub
https://github.com/Gravitate-Health/fhir-connector/issues/2#issuecomment-1752890551,
or unsubscribe
https://github.com/notifications/unsubscribe-auth/ADMJVUGD347W35S4RVEXFZDX6PSRDAVCNFSM6AAAAAA46N5J5GVHI2DSMVQWIX3LMV43OSLTON2WKQ3PNVWWK3TUHMYTONJSHA4TANJVGE
.
You are receiving this because you were mentioned.Message ID:
@.***>

I'm asking again. By the moment I've made this PR to HL7 repo meanwhile I'm waiting
https://github.com/hl7-eu/gravitate-health/compare/master...aalonsolopez:gravitate-health:patch-1

asking again? who? didnt understand
Accepted the PR
Alejandro Alonso @.***> escreveu no dia segunda,
9/10/2023 à(s) 13:16:

I'm asking again. By the moment I've made this PR to HL7 repo meanwhile
I'm waiting
@.***:gravitate-health:patch-1
https://github.com/hl7-eu/gravitate-health/compare/master...aalonsolopez:gravitate-health:patch-1
—
Reply to this email directly, view it on GitHub
https://github.com/Gravitate-Health/fhir-connector/issues/2#issuecomment-1752900648,
or unsubscribe
https://github.com/notifications/unsubscribe-auth/ADMJVUBBI7F2MT7KJKPGJ7TX6PTLPAVCNFSM6AAAAAA46N5J5GVHI2DSMVQWIX3LMV43OSLTON2WKQ3PNVWWK3TUHMYTONJSHEYDANRUHA
.
You are receiving this because you were mentioned.Message ID:
@.***>

asking again? who? didnt understand Accepted the PR Alejandro Alonso @.> escreveu no dia segunda, 9/10/2023 à(s) 13:16:
…
I'm asking again. By the moment I've made this PR to HL7 repo meanwhile I'm waiting @.:gravitate-health:patch-1 <hl7-eu/gravitate-health@master...aalonsolopez:gravitate-health:patch-1> — Reply to this email directly, view it on GitHub <#2 (comment)>, or unsubscribe https://github.com/notifications/unsubscribe-auth/ADMJVUBBI7F2MT7KJKPGJ7TX6PTLPAVCNFSM6AAAAAA46N5J5GVHI2DSMVQWIX3LMV43OSLTON2WKQ3PNVWWK3TUHMYTONJSHEYDANRUHA . You are receiving this because you were mentioned.Message ID: @.***>

Our QA

AH! Great! thanks
Alejandro Alonso @.***> escreveu no dia segunda,
9/10/2023 à(s) 13:19:

asking again? who? didnt understand Accepted the PR Alejandro Alonso @.
> escreveu no dia segunda, 9/10/2023 à(s) 13:16: …
<#m_-2481782322839293119_> I'm asking again. By the moment I've made this
PR to HL7 repo meanwhile I'm waiting @.:gravitate-health:patch-1 <
@.:gravitate-health:patch-1
https://github.com/hl7-eu/gravitate-health/compare/master...aalonsolopez:gravitate-health:patch-1>
— Reply to this email directly, view it on GitHub <#2 (comment)
https://github.com/Gravitate-Health/fhir-connector/issues/2#issuecomment-1752900648>,
or unsubscribe
https://github.com/notifications/unsubscribe-auth/ADMJVUBBI7F2MT7KJKPGJ7TX6PTLPAVCNFSM6AAAAAA46N5J5GVHI2DSMVQWIX3LMV43OSLTON2WKQ3PNVWWK3TUHMYTONJSHEYDANRUHA
. You are receiving this because you were mentioned.Message ID: @.>
Our QA
—
Reply to this email directly, view it on GitHub
https://github.com/Gravitate-Health/fhir-connector/issues/2#issuecomment-1752904472,
or unsubscribe
https://github.com/notifications/unsubscribe-auth/ADMJVUFTP4PGMNUPEQNOW7LX6PTVPAVCNFSM6AAAAAA46N5J5GVHI2DSMVQWIX3LMV43OSLTON2WKQ3PNVWWK3TUHMYTONJSHEYDINBXGI
.
You are receiving this because you were mentioned.Message ID:
@.***>

@aalonsolopez when can I do a rerun on the fixed data?

@aalonsolopez when can I do a rerun on the fixed data?

When the connector reactivates its job, idk when it should rerun. Maybe the best option is to implement an HTML validator that verifies that every div section has no HTML Validation Errors.

Lens Selector v0.2.0 is live now on the same lenses as before
https://github.com/Gravitate-Health/lens-selector-mvp2/releases/tag/v0.2.0

you are probably right
Alejandro Alonso @.***> escreveu no dia segunda,
9/10/2023 à(s) 13:34:

@aalonsolopez https://github.com/aalonsolopez when can I do a rerun on
the fixed data?
When the connector reactivates its job, idk when it should rerun. Maybe
the best option is to implement an HTML validator that verifies that every
div section has no HTML Validation Errors.
—
Reply to this email directly, view it on GitHub
https://github.com/Gravitate-Health/fhir-connector/issues/2#issuecomment-1752928490,
or unsubscribe
https://github.com/notifications/unsubscribe-auth/ADMJVUFDDHFQBFVKNDFECEDX6PVPDAVCNFSM6AAAAAA46N5J5GVHI2DSMVQWIX3LMV43OSLTON2WKQ3PNVWWK3TUHMYTONJSHEZDQNBZGA
.
You are receiving this because you were mentioned.Message ID:
@.***>

By the way, thank you for the patience while the release was freezed 😞 I hope everything works fine, and I'm assuming that there's a lot more to do, but don't doubt on open issues in https://github.com/Gravitate-Health/lens-selector-mvp2/issues if you find something that it's not working as expected

@aalonsolopez when can I do a rerun on the fixed data?

When the connector reactivates its job, idk when it should rerun. Maybe the best option is to implement an HTML validator that verifies that every div section has no HTML Validation Errors.

When is that? Because its still broken

As soon as I can I'll investigate it or try to launch it manually

Please communicate in absolute terms - eg. in 1 hour or in 1 day or in 1 week.

In about one hour

Solved @jkiddo

So its still broken

Ok, all the ePIs need to pass an HTML validation then... There's nothing I can do rn

@joofio can you fix that?

how did you get that validation? I copied the xhtml to the w3c validator
and the only error i get are about titles and .
i changed the list to span to test nevertheless
Jens Kristian Villadsen @.***> escreveu no dia segunda,
9/10/2023 à(s) 16:23:

@joofio https://github.com/joofio can you fix that?
—
Reply to this email directly, view it on GitHub
https://github.com/Gravitate-Health/fhir-connector/issues/2#issuecomment-1753219393,
or unsubscribe
https://github.com/notifications/unsubscribe-auth/ADMJVUANSOASXJWNL3EM7RTX6QJHFAVCNFSM6AAAAAA46N5J5GVHI2DSMVQWIX3LMV43OSLTON2WKQ3PNVWWK3TUHMYTONJTGIYTSMZZGM
.
You are receiving this because you were mentioned.Message ID:
@.***>

I used this https://validator.w3.org/#validate_by_input

furthermore, i have tested (what i believe) are Jens tests and dont get the same results.
added HTTP tests https://github.com/hl7-eu/gravitate-health/blob/ba91d9f8c8b0f40ce0faa986c20f5b15b866e961/tests.http#L64 and https://github.com/hl7-eu/gravitate-health/blob/ba91d9f8c8b0f40ce0faa986c20f5b15b866e961/tests.http#L72
these are returning html data at the moment

how did you get that validation? I copied the xhtml to the w3c validator
and the only error i get are about titles and .
i changed the list to span to test nevertheless
Jens Kristian Villadsen @.***> escreveu no dia segunda,
9/10/2023 à(s) 16:23:

@joofio https://github.com/joofio can you fix that?
—
Reply to this email directly, view it on GitHub
#2 (comment),
or unsubscribe
https://github.com/notifications/unsubscribe-auth/ADMJVUANSOASXJWNL3EM7RTX6QJHFAVCNFSM6AAAAAA46N5J5GVHI2DSMVQWIX3LMV43OSLTON2WKQ3PNVWWK3TUHMYTONJTGIYTSMZZGM
.
You are receiving this because you were mentioned.Message ID:
@.***>

I used this https://validator.w3.org/#validate_by_input

if i go there, and paste
<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Dovato</p>
<ul>
<li>if you are allergic (hypersensitive) to dolutegravir or lamivudine or any of the other ingredients of
this medicine (listed in section 6).</li>
<li>If you are taking a medicine called fampridine (also known as dalfampridine; used in multiple
sclerosis).</li>
<li>If you think any of these apply to you, tell your doctor.
Warnings and precautions
Some people taking Dovato or other combination treatments for HIV are more at risk of serious side effects
than others. You need to be aware of the extra risks:</li>
<li><span class="liver">if you have moderate or severe liver disease </span>
if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection, don’t
stop Dovato without your doctor’s advice, as your hepatitis may come back)
• if you have a kidney problem.
→ Talk to your doctor before using Dovato if any of these apply to you. You may need extra checkups, including blood tests, while you’re taking your medicine. See section 4 for more information.
Allergic reactions
Dovato contains dolutegravir. Dolutegravir can cause a serious allergic reaction known as a hypersensitivity
reaction. You need to know about important signs and symptoms to look out for while you’re taking Dovato.
→ Read the information ‘Allergic reactions’ in section 4 of this leaflet.
Look out for important symptoms
Some people taking medicines for HIV infection develop other conditions, which can be serious. These
include:
• symptoms of infections and inflammation
• joint pain, stiffness and bone problems.
You need to know about important signs and symptoms to look out for while you’re taking Dovato.
→ Read the information ‘Other possible side effects’ in section 4 of this leaflet.</li>
</ul>
<p><strong>Children</strong></p>
<p>This medicine is not for use in children under 12 years of age, because it has not been studied in these
patients.</p>
<p><strong>Other medicines and Dovato</strong></p>
<p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p>
<p>Don't take Dovato with the following medicine:</p>
<ul>
<li>fampridine (also known as dalfampridine), used in <strong>multiple sclerosis.</strong></li>
</ul>
<p>Some medicines can affect how Dovato works or make it more likely that you will have side effects. Dovato
can also affect how some other medicines work.</p>
<p>Tell your doctor if you are taking any of the medicines in the following list:</p>
<ul>
<li>metformin, to treat diabetes</li>
<li>medicines called antacids, to treat indigestion and heartburn. Do not take an antacid during the
6 hours before you take Dovato, or for at least 2 hours after you take it (see also section 3, ‘How to
take Dovato’)</li>
<li>supplements or multivitamins containing calcium, iron or magnesium. If you take Dovato with
food, you can take supplements or multivitamins containing calcium, iron or magnesium at the same
time as Dovato. If you do not take Dovato with food, do not take a supplement or multivitamin
containing calcium, iron or magnesium during the 6 hours before you take Dovato, or for at least
2 hours after you take it (see also section 3, ‘How to take Dovato’)</li>
<li>emtricitabine, etravirine, efavirenz, nevirapine or tipranavir/ritonavir, to treat HIV infection</li>
<li>medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol,
lactitol or maltitol), if taken regularly</li>
<li>cladribine, to treat leukaemia or multiple sclerosis</li>
<li>rifampicin, to treat tuberculosis (TB) and other bacterial infections</li>
<li>phenytoin and phenobarbital, to treat epilepsy</li>
<li>oxcarbazepine and carbamazepine, to treat epilepsy or bipolar disorder</li>
<li class="contra-indication-hypericum"><p>St. John’s wort (Hypericum perforatum), a herbal remedy to treat depression.</p>
</li>
<li><p>Tell your doctor or pharmacist if you are taking any of these. Your doctor may decide to adjust
your dose or that you need extra check ups.</p>
</li>
</ul>
<div class="pregnancyCategory"><p><strong>Pregnancy</strong></p>
<p>If you are pregnant, think you may be pregnant, or if you are planning to have a baby:</p>
<ul>
<li>Talk to your doctor about the risks and benefits of taking Dovato.</li>
</ul>
<p>Taking Dovato at the time of becoming pregnant or during the first six weeks of pregnancy, may increase the
risk of a birth defect, called neural tube defect, such as spina bifida (malformed spinal cord).</p>
<p>If you could get pregnant while taking Dovato:</p>
<ul>
<li>Talk to your doctor and discuss whether there is a need for contraception, such as condom or
pills.</li>
</ul>
<p>Tell your doctor immediately if you become pregnant or are planning to become pregnant. Your doctor will
review your treatment. Do not stop taking Dovato without consulting your doctor, as this may harm you and
your unborn child.</p>
<p><strong>Breast-feeding</strong></p>
<p>Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to
the baby in breast milk.
A small amount of the ingredients in Dovato can also pass into your breast milk.
If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon
as possible.</p>
</div>
<p><strong>Driving and using machines</strong></p>
<p>Dovato can make you dizzy, and have other side effects that make you less alert.</p>
<ul>
<li>Don’t drive or operate machinery unless you are sure you’re not affected.</li>
</ul>         </div>

it returns 3 errors/warnings:

what am i missing?

The response from the service looks like this:
"div": "\u003cp\u003eDo not take Dovato\u003c/p\u003e\u003cul\u003e\u003cli\u003eif you are allergic (hypersensitive) to dolutegravir or lamivudine or any of the other ingredients of this medicine (listed in section 6).\u003c/li\u003e\u003cli\u003eIf you are taking a medicine called fampridine (also known as dalfampridine; used in multiple sclerosis).\u003c/li\u003e\u003cli\u003eIf you think any of these apply to you, tell your doctor. Warnings and precautions Some people taking Dovato or other combination treatments for HIV are more at risk of serious side effects than others. You need to be aware of the extra risks:\u003c/li\u003e\u003cli\u003e\u003cdiv class\u003d\"liver\"\u003eif you have moderate or severe liver disease\u003c/div\u003eif you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection, don’t stop Dovato without your doctor’s advice, as your hepatitis may come back) • if you have a kidney problem. → Talk to your doctor before using Dovato if any of these apply to you. You may need extra checkups, including blood tests, while you’re taking your medicine. See section 4 for more information. Allergic reactions Dovato contains dolutegravir. Dolutegravir can cause a serious allergic reaction known as a hypersensitivity reaction. You need to know about important signs and symptoms to look out for while you’re taking Dovato. → Read the information ‘Allergic reactions’ in section 4 of this leaflet. Look out for important symptoms Some people taking medicines for HIV infection develop other conditions, which can be serious. These include: • symptoms of infections and inflammation • joint pain, stiffness and bone problems. You need to know about important signs and symptoms to look out for while you’re taking Dovato. → Read the information ‘Other possible side effects’ in section 4 of this leaflet.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u003cstrong\u003eChildren\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eThis medicine is not for use in children under 12 years of age, because it has not been studied in these patients.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eOther medicines and Dovato\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eTell your doctor if you are taking, have recently taken or might take any other medicines.\u003c/p\u003e\u003cp\u003eDon\u0027t take Dovato with the following medicine:\u003c/p\u003e\u003cul\u003e\u003cli\u003efampridine (also known as dalfampridine), used in \u003cstrong\u003emultiple sclerosis.\u003c/strong\u003e\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eSome medicines can affect how Dovato works or make it more likely that you will have side effects. Dovato can also affect how some other medicines work.\u003c/p\u003e\u003cp\u003eTell your doctor if you are taking any of the medicines in the following list:\u003c/p\u003e\u003cul\u003e\u003cli\u003emetformin, to treat diabetes\u003c/li\u003e\u003cli\u003emedicines called antacids, to treat indigestion and heartburn. Do not take an antacid during the 6 hours before you take Dovato, or for at least 2 hours after you take it (see also section 3, ‘How to take Dovato’)\u003c/li\u003e\u003cli\u003esupplements or multivitamins containing calcium, iron or magnesium. If you take Dovato with food, you can take supplements or multivitamins containing calcium, iron or magnesium at the same time as Dovato. If you do not take Dovato with food, do not take a supplement or multivitamin containing calcium, iron or magnesium during the 6 hours before you take Dovato, or for at least 2 hours after you take it (see also section 3, ‘How to take Dovato’)\u003c/li\u003e\u003cli\u003eemtricitabine, etravirine, efavirenz, nevirapine or tipranavir/ritonavir, to treat HIV infection\u003c/li\u003e\u003cli\u003emedicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly\u003c/li\u003e\u003cli\u003ecladribine, to treat leukaemia or multiple sclerosis\u003c/li\u003e\u003cli\u003erifampicin, to treat tuberculosis (TB) and other bacterial infections\u003c/li\u003e\u003cli\u003ephenytoin and phenobarbital, to treat epilepsy\u003c/li\u003e\u003cli\u003eoxcarbazepine and carbamazepine, to treat epilepsy or bipolar disorder\u003c/li\u003e\u003cli class\u003d\"contra-indication-hypericum\"\u003e\u003cp\u003eSt. John’s wort (Hypericum perforatum), a herbal remedy to treat depression.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eTell your doctor or pharmacist if you are taking any of these. Your doctor may decide to adjust your dose or that you need extra check ups.\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003cdiv class\u003d\"pregnancyCategory highlight\"\u003e\u003cp\u003e\u003cstrong\u003ePregnancy\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eIf you are pregnant, think you may be pregnant, or if you are planning to have a baby:\u003c/p\u003e\u003cul\u003e\u003cli\u003eTalk to your doctor about the risks and benefits of taking Dovato.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eTaking Dovato at the time of becoming pregnant or during the first six weeks of pregnancy, may increase the risk of a birth defect, called neural tube defect, such as spina bifida (malformed spinal cord).\u003c/p\u003e\u003cp\u003eIf you could get pregnant while taking Dovato:\u003c/p\u003e\u003cul\u003e\u003cli\u003eTalk to your doctor and discuss whether there is a need for contraception, such as condom or pills.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eTell your doctor immediately if you become pregnant or are planning to become pregnant. Your doctor will review your treatment. Do not stop taking Dovato without consulting your doctor, as this may harm you and your unborn child.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBreast-feeding\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eBreast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk. A small amount of the ingredients in Dovato can also pass into your breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.\u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cstrong\u003eDriving and using machines\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eDovato can make you dizzy, and have other side effects that make you less alert.\u003c/p\u003e\u003cul\u003e\u003cli\u003eDon’t drive or operate machinery unless you are sure you’re not affected.\u003c/li\u003e\u003c/ul\u003e"

Comparing it to other sections it looks like its missing a div tag for starters - e.g. \u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e

Unproblematic:
"div": "\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003eWhat in this leaflet\u003col\u003e\u003cli\u003eWhat Dovato is and what it is used for\u003c/li\u003e\u003cli\u003eWhat you need to know before you take Dovato\u003c/li\u003e\u003cli\u003eHow to take Dovato\u003c/li\u003e\u003cli\u003ePossible side effects\u003c/li\u003e\u003cli\u003eHow to store Dovato\u003c/li\u003e\u003cli\u003eContents of the pack and other information\u003c/li\u003e\u003c/ol\u003e\u003c/div\u003e"
Problematic:
"div": "\u003cp\u003eDo not take Dovato\u003c/p\u003e\u003cul\u003e\u003cli\u003eif you are allergic (hypersensitive) to dolutegravir or lamivudine or any of the other ingredients of this medicine (listed in section 6).\u003c/li\u003e\u003cli\u003eIf you are taking a medicine called fampridine (also known as dalfampridine; used in multiple sclerosis).\u003c/li\u003e\u003cli\u003eIf you think any of these apply to you, tell your doctor. Warnings and precautions Some people taking Dovato or other combination treatments for HIV are more at risk of serious side effects than others. You need to be aware of the extra risks:\u003c/li\u003e\u003cli\u003e\u003cdiv class\u003d\"liver\"\u003eif you have moderate or severe liver disease\u003c/div\u003eif you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection, don’t stop Dovato without your doctor’s advice, as your hepatitis may come back) • if you have a kidney problem. → Talk to your doctor before using Dovato if any of these apply to you. You may need extra checkups, including blood tests, while you’re taking your medicine. See section 4 for more information. Allergic reactions Dovato contains dolutegravir. Dolutegravir can cause a serious allergic reaction known as a hypersensitivity reaction. You need to know about important signs and symptoms to look out for while you’re taking Dovato. → Read the information ‘Allergic reactions’ in section 4 of this leaflet. Look out for important symptoms Some people taking medicines for HIV infection develop other conditions, which can be serious. These include: • symptoms of infections and inflammation • joint pain, stiffness and bone problems. You need to know about important signs and symptoms to look out for while you’re taking Dovato. → Read the information ‘Other possible side effects’ in section 4 of this leaflet.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u003cstrong\u003eChildren\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eThis medicine is not for use in children under 12 years of age, because it has not been studied in these patients.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eOther medicines and Dovato\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eTell your doctor if you are taking, have recently taken or might take any other medicines.\u003c/p\u003e\u003cp\u003eDon\u0027t take Dovato with the following medicine:\u003c/p\u003e\u003cul\u003e\u003cli\u003efampridine (also known as dalfampridine), used in \u003cstrong\u003emultiple sclerosis.\u003c/strong\u003e\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eSome medicines can affect how Dovato works or make it more likely that you will have side effects. Dovato can also affect how some other medicines work.\u003c/p\u003e\u003cp\u003eTell your doctor if you are taking any of the medicines in the following list:\u003c/p\u003e\u003cul\u003e\u003cli\u003emetformin, to treat diabetes\u003c/li\u003e\u003cli\u003emedicines called antacids, to treat indigestion and heartburn. Do not take an antacid during the 6 hours before you take Dovato, or for at least 2 hours after you take it (see also section 3, ‘How to take Dovato’)\u003c/li\u003e\u003cli\u003esupplements or multivitamins containing calcium, iron or magnesium. If you take Dovato with food, you can take supplements or multivitamins containing calcium, iron or magnesium at the same time as Dovato. If you do not take Dovato with food, do not take a supplement or multivitamin containing calcium, iron or magnesium during the 6 hours before you take Dovato, or for at least 2 hours after you take it (see also section 3, ‘How to take Dovato’)\u003c/li\u003e\u003cli\u003eemtricitabine, etravirine, efavirenz, nevirapine or tipranavir/ritonavir, to treat HIV infection\u003c/li\u003e\u003cli\u003emedicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly\u003c/li\u003e\u003cli\u003ecladribine, to treat leukaemia or multiple sclerosis\u003c/li\u003e\u003cli\u003erifampicin, to treat tuberculosis (TB) and other bacterial infections\u003c/li\u003e\u003cli\u003ephenytoin and phenobarbital, to treat epilepsy\u003c/li\u003e\u003cli\u003eoxcarbazepine and carbamazepine, to treat epilepsy or bipolar disorder\u003c/li\u003e\u003cli class\u003d\"contra-indication-hypericum\"\u003e\u003cp\u003eSt. John’s wort (Hypericum perforatum), a herbal remedy to treat depression.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eTell your doctor or pharmacist if you are taking any of these. Your doctor may decide to adjust your dose or that you need extra check ups.\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003cdiv class\u003d\"pregnancyCategory highlight\"\u003e\u003cp\u003e\u003cstrong\u003ePregnancy\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eIf you are pregnant, think you may be pregnant, or if you are planning to have a baby:\u003c/p\u003e\u003cul\u003e\u003cli\u003eTalk to your doctor about the risks and benefits of taking Dovato.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eTaking Dovato at the time of becoming pregnant or during the first six weeks of pregnancy, may increase the risk of a birth defect, called neural tube defect, such as spina bifida (malformed spinal cord).\u003c/p\u003e\u003cp\u003eIf you could get pregnant while taking Dovato:\u003c/p\u003e\u003cul\u003e\u003cli\u003eTalk to your doctor and discuss whether there is a need for contraception, such as condom or pills.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eTell your doctor immediately if you become pregnant or are planning to become pregnant. Your doctor will review your treatment. Do not stop taking Dovato without consulting your doctor, as this may harm you and your unborn child.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBreast-feeding\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eBreast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk. A small amount of the ingredients in Dovato can also pass into your breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.\u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cstrong\u003eDriving and using machines\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eDovato can make you dizzy, and have other side effects that make you less alert.\u003c/p\u003e\u003cul\u003e\u003cli\u003eDon’t drive or operate machinery unless you are sure you’re not affected.\u003c/li\u003e\u003c/ul\u003e"
Unproblematic:
"div": "\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003eAlways take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.\u003c/p\u003e\u003cul\u003e\u003cli\u003eThe recommended dose of Dovato is one tablet once a day.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eSwallow the tablet with some liquid. Dovato can be taken with or without food.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eUse in adolescents\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eAdolescents aged between 12 and 17 years and weighing at least 40 kg can take the adult dose of one tablet once a day.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eAntacid medicines\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eAntacids, to treat indigestion and heartburn, can stop Dovato being absorbed into your body and make it less effective. Do not take an antacid during the 6 hours before you take Dovato, or for at least 2 hours after you take it. You can take other acid-lowering medicines like ranitidine and omeprazole at the same time as Dovato.\u003c/p\u003e\u003cul\u003e\u003cli\u003eTalk to your doctor for further advice on taking acid-lowering medicines with Dovato.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u003cstrong\u003eSupplements or multivitamins containing calcium, iron or magnesium\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eSupplements or multivitamins containing calcium, iron or magnesium can stop Dovato being absorbed into your body and make it less effective. If you take Dovato with food, you can take supplements or multivitamins containing calcium, iron or magnesium at the same time as Dovato. If you do not take Dovato with food, do not take a supplement or multivitamin containing calcium, iron or magnesium during the 6 hours before you take Dovato, or for at least 2 hours after you take it.\u003c/p\u003e\u003cul\u003e\u003cli\u003eTalk to your doctor for further advice on taking supplements or multivitamins containing calcium, iron or magnesium with Dovato.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u003cstrong\u003eIf you take more Dovato than you should\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eIf you take too many tablets of Dovato contact your doctor or pharmacist for advice. If possible, show them the Dovato pack.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eIf you forget to take Dovato\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eIf you miss a dose, take it as soon as you remember. But if your next dose is due within 4 hours, skip the dose you missed and take the next one at the usual time. Then continue your treatment as before.\u003c/p\u003e\u003cul\u003e\u003cli\u003eDo not take a double dose to make up for a forgotten dose.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u003cstrong\u003eDon’t stop taking Dovato without advice from your doctor\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eTake Dovato for as long as your doctor recommends. Don’t stop unless your doctor tells you to. Stopping Dovato can affect your health and how future treatment works.\u003c/p\u003e\u003cp\u003eIf you have any further questions on the use of this medicine, ask your doctor or pharmacist.\u003c/p\u003e\u003c/div\u003e"

But you have an error on your side due to the divs ?
Seems focusing is removing the divs ?
Jens Kristian Villadsen @.***> escreveu em seg.,
9/10/2023 às 21:09 :

Unproblematic:
"div": "\u003cdiv xmlns\u003d"http://www.w3.org/1999/xhtml\"\u003eWhat
in this leaflet\u003col\u003e\u003cli\u003eWhat Dovato is and what it is
used for\u003c/li\u003e\u003cli\u003eWhat you need to know before you take
Dovato\u003c/li\u003e\u003cli\u003eHow to take
Dovato\u003c/li\u003e\u003cli\u003ePossible side
effects\u003c/li\u003e\u003cli\u003eHow to store
Dovato\u003c/li\u003e\u003cli\u003eContents of the pack and other
information\u003c/li\u003e\u003c/ol\u003e\u003c/div\u003e"
Problematic:
"div": "\u003cp\u003eDo not take
Dovato\u003c/p\u003e\u003cul\u003e\u003cli\u003eif you are allergic
(hypersensitive) to dolutegravir or lamivudine or any of the other
ingredients of this medicine (listed in section
6).\u003c/li\u003e\u003cli\u003eIf you are taking a medicine called
fampridine (also known as dalfampridine; used in multiple
sclerosis).\u003c/li\u003e\u003cli\u003eIf you think any of these apply to
you, tell your doctor. Warnings and precautions Some people taking Dovato
or other combination treatments for HIV are more at risk of serious side
effects than others. You need to be aware of the extra
risks:\u003c/li\u003e\u003cli\u003e\u003cdiv class\u003d"liver"\u003eif
you have moderate or severe liver disease\u003c/div\u003eif you have ever
had liver disease, including hepatitis B or C (if you have hepatitis B
infection, don’t stop Dovato without your doctor’s advice, as your
hepatitis may come back) • if you have a kidney problem. → Talk to your
doctor before using Dovato if any of these apply to you. You may need extra
checkups, including blood tests, while you’re taking your medicine. See
section 4 for more information. Allergic reactions Dovato contains
dolutegravir. Dolutegravir can cause a serious allergic reaction known as a
hypersensitivity reaction. You need to know about important signs and
symptoms to look out for while you’re taking Dovato. → Read the information
‘Allergic reactions’ in section 4 of this leaflet. Look out for important
symptoms Some people taking medicines for HIV infection develop other
conditions, which can be serious. These include: • symptoms of infections
and inflammation • joint pain, stiffness and bone problems. You need to
know about important signs and symptoms to look out for while you’re taking
Dovato. → Read the information ‘Other possible side effects’ in section 4
of this
leaflet.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u003cstrong\u003eChildren\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eThis
medicine is not for use in children under 12 years of age, because it has
not been studied in these
patients.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eOther medicines and
Dovato\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eTell your doctor if you
are taking, have recently taken or might take any other
medicines.\u003c/p\u003e\u003cp\u003eDon\u0027t take Dovato with the
following medicine:\u003c/p\u003e\u003cul\u003e\u003cli\u003efampridine
(also known as dalfampridine), used in \u003cstrong\u003emultiple
sclerosis.\u003c/strong\u003e\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eSome
medicines can affect how Dovato works or make it more likely that you will
have side effects. Dovato can also affect how some other medicines
work.\u003c/p\u003e\u003cp\u003eTell your doctor if you are taking any of
the medicines in the following
list:\u003c/p\u003e\u003cul\u003e\u003cli\u003emetformin, to treat
diabetes\u003c/li\u003e\u003cli\u003emedicines called antacids, to treat
indigestion and heartburn. Do not take an antacid during the 6 hours before
you take Dovato, or for at least 2 hours after you take it (see also
section 3, ‘How to take Dovato’)\u003c/li\u003e\u003cli\u003esupplements or
multivitamins containing calcium, iron or magnesium. If you take Dovato
with food, you can take supplements or multivitamins containing calcium,
iron or magnesium at the same time as Dovato. If you do not take Dovato
with food, do not take a supplement or multivitamin containing calcium,
iron or magnesium during the 6 hours before you take Dovato, or for at
least 2 hours after you take it (see also section 3, ‘How to take
Dovato’)\u003c/li\u003e\u003cli\u003eemtricitabine, etravirine, efavirenz,
nevirapine or tipranavir/ritonavir, to treat HIV
infection\u003c/li\u003e\u003cli\u003emedicines (usually liquids)
containing sorbitol and other sugar alcohols (such as xylitol, mannitol,
lactitol or maltitol), if taken
regularly\u003c/li\u003e\u003cli\u003ecladribine, to treat leukaemia or
multiple sclerosis\u003c/li\u003e\u003cli\u003erifampicin, to treat
tuberculosis (TB) and other bacterial
infections\u003c/li\u003e\u003cli\u003ephenytoin and phenobarbital, to
treat epilepsy\u003c/li\u003e\u003cli\u003eoxcarbazepine and carbamazepine,
to treat epilepsy or bipolar disorder\u003c/li\u003e\u003cli
class\u003d"contra-indication-hypericum"\u003e\u003cp\u003eSt. John’s
wort (Hypericum perforatum), a herbal remedy to treat
depression.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eTell
your doctor or pharmacist if you are taking any of these. Your doctor may
decide to adjust your dose or that you need extra check
ups.\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003cdiv
class\u003d"pregnancyCategory
highlight"\u003e\u003cp\u003e\u003cstrong\u003ePregnancy\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eIf
you are pregnant, think you may be pregnant, or if you are planning to have
a baby:\u003c/p\u003e\u003cul\u003e\u003cli\u003eTalk to your doctor about
the risks and benefits of taking
Dovato.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eTaking Dovato at the time
of becoming pregnant or during the first six weeks of pregnancy, may
increase the risk of a birth defect, called neural tube defect, such as
spina bifida (malformed spinal cord).\u003c/p\u003e\u003cp\u003eIf you
could get pregnant while taking
Dovato:\u003c/p\u003e\u003cul\u003e\u003cli\u003eTalk to your doctor and
discuss whether there is a need for contraception, such as condom or
pills.\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eTell your doctor
immediately if you become pregnant or are planning to become pregnant. Your
doctor will review your treatment. Do not stop taking Dovato without
consulting your doctor, as this may harm you and your unborn
child.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBreast-feeding\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eBreast-feeding
is not recommended in women living with HIV because HIV infection can be
passed on to the baby in breast milk. A small amount of the ingredients in
Dovato can also pass into your breast milk. If you are breast-feeding, or
thinking about breast-feeding, you should discuss it with your doctor as
soon as
possible.\u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cstrong\u003eDriving